NASH MOA Study commences with SanyalBio & Duke University
Filed with ASX · · 3 pages · English
Earlier from Immuron
- Immuron Receives $1.6M R&D Tax Concession Refund
- Immurons NASH Phase II Trial Achieves 100 Patient Milestone
- NASH Phase II Trial reaches 75% of Patient Recruitment
- Immurons $6M Rights Issue Closes Oversubscribed
- Appendix 4E and Annual Report
Later from Immuron
- First Patient in Pediatric Fatty-Liver Phase II Trial
- Immuron Completes Phase II NASH Clinical Trial Recruitment
- Appendix 4D - Half Year Report and Accounts - Dec 2016
- Close of Recruitment of Phase II NASH Trial
- Positive Results of IMM-124E in Acute Colitis Studies
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron